E-field Guided iTBS for Treatment Resistant Depression
The purpose of this study is to establish how personalization of repetitive transcranial magnetic stimulation (rTMS) can change markers of brain activity and improve treatment response. To do this, all participants will receive the same active form of treatments, but some of the participants in this study will receive
| Condition(s) | Major Depressive Disorder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose of this study is to establish how personalization of repetitive transcranial magnetic stimulation (rTMS) can change markers of brain activity and improve treatment response. To do this, all participants will receive the same active form of treatments, but some of the participants in this study will receive intermittent theta burst stimulation (iTBS) rTMS treatment with standard forms of targeting and intensity, and others will receive iTBS rTMS treatment using personalized magnetic resonance imaging (MRI) and electric field (E-field) modeling measures. |
| Who can participate | Inclusion Criteria: 1. are outpatients; 2. are voluntary and competent to consent to treatment; 3. have a Diagnostic and Statistical Manual for Mental Disorders, 5th edition major depressive episode based on the Mini International Neuropsychiatric Interview (MINI) 4. are 18yo to 65yo; 5. have a score of ≥18 on the Hamilton Rating Scale for Depression (HRSD-17) item at screening 6. have not had a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of ≥ 3 in the current episode or have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF 1 or 2); 7. are agreeable to keeping their current medication constant during the study 8. are able to adhere to the study and treatm |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Centre for Addiction and Mental Health |
| Locations | Toronto, Ontario, Canada; Toronto, Ontario, Canada |
| Start date | 2022-10-24 |
| NCT ID | NCT05583747 |
| Official listing | https://clinicaltrials.gov/study/NCT05583747 |